Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Efficacy and Safety in MDD
NCT00672620Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Takeda. Primary endpoint: 24-item Hamilton Depression Scale Total Score at 8 weeks. Started Apr 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00672620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672620.